Spots Global Cancer Trial Database for braf gene mutation
Every month we try and update this database with for braf gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | NCT01531361 | Advanced Malign... BRAF Gene Mutat... Metastatic Mali... Recurrent Malig... Refractory Mali... | Crizotinib Laboratory Biom... Pharmacological... Sorafenib Tosyl... Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | NCT04488003 | Advanced Solid ... BRAF Gene Mutat... BRAF Gene Alter... MEK Mutation MEK Alteration MAP2K1 Gene Mut... MAP2K1 Gene Alt... MAP2K2 Gene Mut... MAP2K2 Gene Alt... | Ulixertinib Physician's Cho... | 18 Years - | BioMed Valley Discoveries, Inc | |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - | NCT03750175 | Colorectal Canc... Circulating Tum... KRAS Gene Mutat... NRAS Gene Mutat... BRAF Gene Mutat... Epidermal Growt... | Plasma circulat... | 18 Years - | Aarhus University Hospital | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | NCT04566393 | Pancreatic Canc... Small Bowel Can... Colorectal Canc... Melanoma Non Small Cell ... Thyroid Cancer Bladder Cancer Head and Neck C... Gastric Cancer Esophageal Canc... Cholangiocarcin... Ovarian Cancer Hepatocellular ... Glioblastoma MAPK Gene Mutat... KRAS Activating... BRAF Gene Mutat... NRAS Gene Mutat... HRAS Gene Mutat... MEK Mutation ERK Mutation | Ulixertinib (BV... | 12 Years - | xCures | |
| Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma | NCT06264778 | Ameloblastoma | Dabrafenib | 18 Years - 65 Years | Shandong University | |
| Continued Access to RXDX-105 | NCT03784378 | Non Small Cell ... Ovarian Cancer RET Gene Mutati... BRAF Gene Mutat... | RXDX-105 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma | NCT06264778 | Ameloblastoma | Dabrafenib | 18 Years - 65 Years | Shandong University | |
| Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | NCT04903119 | Metastatic Mela... BRAF Gene Mutat... | Nilotinib 100mg Nilotinib 200mg Nilotinib 300mg Nilotinib 400mg Dabrafenib Trametinib | 18 Years - | University of Kentucky | |
| Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | NCT04903119 | Metastatic Mela... BRAF Gene Mutat... | Nilotinib 100mg Nilotinib 200mg Nilotinib 300mg Nilotinib 400mg Dabrafenib Trametinib | 18 Years - | University of Kentucky | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - | NCT03750175 | Colorectal Canc... Circulating Tum... KRAS Gene Mutat... NRAS Gene Mutat... BRAF Gene Mutat... Epidermal Growt... | Plasma circulat... | 18 Years - | Aarhus University Hospital | |
| Dabrafenib and/or Trametinib Rollover Study | NCT03340506 | Melanoma Non Small Cell ... Solid Tumor Rare Cancers High Grade Glio... | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | NCT02367859 | Ameloblastoma BRAF Gene Mutat... | Dabrafenib Trametinib | 18 Years - | Stanford University | |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | NCT04488003 | Advanced Solid ... BRAF Gene Mutat... BRAF Gene Alter... MEK Mutation MEK Alteration MAP2K1 Gene Mut... MAP2K1 Gene Alt... MAP2K2 Gene Mut... MAP2K2 Gene Alt... | Ulixertinib Physician's Cho... | 18 Years - | BioMed Valley Discoveries, Inc | |
| Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer | NCT02751177 | Colorectal Canc... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
